Short answer
Penumbra Inc (PEN) filed its Q2 2016 10-Q quarterly report on Aug 9, 2016 for the quarter ended Jun 30, 2016.
Penumbra Inc Q2 2016 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $65.1M, up 53.9% YoY from $42.3M
- Peripheral Vascular strongest segment: $19.7M, up 149.6% YoY from $7.9M
- Gross margin 63.7% vs 64.7%; operating margin (1.0%) vs (9.0%) YoY
- Cash $13.9M vs $19.5M at December 31, 2015; operating cash use $12.6M in six months
- Outlook: continued R&D, salesforce and international investment; competition and quarterly variability remain headwinds
Risk Factors
- No material changes to reported risks since the December 31, 2015 Form 10-K
- No new risk factors identified in the quarter
- Carried-forward risks remain governed by the March 8, 2016 annual filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.